Gastroenterology

science-innovation-3

Gastroenterology

Ferring has a long heritage in supporting gastroenterology patients and a series of developmental initiatives are underway to bring new products to this community.

Gastroenterology

Ferring will be a leader in specialty areas within gastroenterology.

Our ambition is to pioneer a new era in gastroenterology with a breakthrough microbiota restoration technology, MRTTM, platform. Further, Ferring has a strong heritage of educational support, sponsorship and clinical research within mild to moderate Inflammatory Bowel Disease (IBD). A series of developmental initiatives are underway to bring new products in this indication to market.

A glucagonlike peptide-2 receptor (GLP-2) agonist, discovered by Ferring with strong potential in gastrointestinal and oncology indications, is in early stage development through a partnership.

We have in-licensed a novel selective IL-6 soluble receptor antagonist from Conaris Research Institute AG, a spin-off of Kiel University. This product is being developed for inflammatory bowel disease (IBD) and other immune disorders. Patient Phase I programme is on-going with Phase II planned for 2015.

Ferring’s key product PENTASA® (mesalazine) is approved for the treatment of IBD including Crohn’s disease and ulcerative colitis. Ferring is continuing to develop many different dosageforms for PENTASA® such as tablets, sachets and suppositories to meet changing patient and physician needs.

In 2013 Ferring, together with Cosmo Pharmaceuticals SpA, launched budesonide MMX™, which is indicated for use in ulcerative colitis. Ferring’s license from Cosmo Pharmaceuticals does not include the US and Japan.

The Ferring gastroenterology portfolio also includes bowel preparations – PICOPREP® / PREPOPIK® (sodium picosulphate, magnesium oxide, citric acid) – used to prepare patients for colonoscopy, and GLYPRESSIN® (terlipressin) which is indicated for the treatment of bleeding oesophageal varices. Building on our experience with GLYPRESSIN® Ferring is developing a partial vasopressin-1a receptor agonist for treatment of refractory ascites.

Discover more about inflammatory bowel diseases

and clostridioides difficile infection

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.

OK

Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.

OK

Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals

OK

Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.

OK

Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.

OK

Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.

OK